Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blind, Multiple Ascending Dose, Placebo-controlled, Safety, Tolerability, Efficacy, Pharmacokinetic (PK) and Pharmacodynamic (PD) Phase Ib/IIa Clinical Trial With AC01 in Patients With HFrEF

NCT05642507 is registered in ClinicalTrials.gov with AnaCardio AB as lead sponsor.

NCT NCT05642507
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05642507 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blind, Multiple Ascending Dose, Placebo-controlled, Safety, Tolerability, Efficacy, Pharmacokinetic (PK) and Pharmacodynamic (PD) Phase Ib/IIa Clinical Trial With AC01 in Patients With HFrEF
Lead sponsor
AnaCardio AB
Phase
Phase 1/2
Overall status
Completed
Start date
February 23, 2023
Completion date
October 27, 2025
Enrollment
58 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with reduced ejection fraction